Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism

American Journal of Hematology
Waldemar WysokinskiRobert McBane

Abstract

To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively. The primary effectiveness outcome was venous thromboembolism (VTE) recurrence, and the secondary was mortality. The primary safety outcome was major bleeding, the secondary clinically relevant safety outcome was non-major bleeding (CRNMB), and the third a composite of major and CRNMB. There were 750 patients treated for acute Ca-VTE with apixaban (n = 224), rivaroxaban (n = 163), and enoxaparin (n = 363) within 14 days of diagnosis and for at least 3 months, or until study event. Recurrent VTE was diagnosed in 11 receiving apixaban, 7 receiving rivaroxaban (apixaban vs rivaroxaban hazard ratio (HR) 1.31, 95% confidence interval (95% CI) 0.51-3.36) and 17 in the enoxaparin receiving group (apixaban vs enoxaparin HR 1.14, 95% CI: 0.54, 2.42 and rivaroxaban vs enoxaparin HR 0.85, 95% Cl: 0.36, 2.06). There were 82 deaths in apixaban, 74 rivaroxaban (apixaban vs rivaroxaban HR 1.67, 95% Cl: 1.20, 2.33) and 171 in enoxaparin group (riva...Continue Reading

References

Jul 11, 2003·The New England Journal of Medicine·Agnes Y Y LeeUNKNOWN Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Veno
Aug 5, 2003·The Oncologist·Ajay K KakkarJohn Wong
Feb 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agnes Y Y LeeMark N Levine
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Dec 6, 2006·The American Journal of Medicine·Russell D HullUNKNOWN LITE Trial Investigators
Feb 27, 2007·Journal of Thrombosis and Haemostasis : JTH·A A KhoranaG H Lyman
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Agnes Y Y LeeUNKNOWN CATCH Investigators
Jan 17, 2017·Journal of Thrombosis and Haemostasis : JTH·P GirardP-M Roy
Dec 13, 2017·The New England Journal of Medicine·Gary E RaskobUNKNOWN Hokusai VTE Cancer Investigators
May 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annie M YoungMark Levine
Dec 5, 2018·The New England Journal of Medicine·Marc CarrierUNKNOWN AVERT Investigators
Feb 10, 2019·Mayo Clinic Proceedings·Dalene M Bott-KitslaarWaldemar E Wysokinski
Feb 21, 2019·The New England Journal of Medicine·Alok A KhoranaUNKNOWN CASSINI Investigators

❮ Previous
Next ❯

Citations

Jun 18, 2020·Research and Practice in Thrombosis and Haemostasis·Rupert BauersachsGerald Soff
Jun 17, 2020·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Julia C CambronWaldemar E Wysokinski
May 26, 2021·Current Medical Research and Opinion·Alexander T CohenXuemei Luo
Jul 8, 2021·Journal of the American Pharmacists Association : JAPhA·Ryan CaputoJona Lekura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.